Merck Sharp & Dohme LLC (MSD) has synthesized new benzimidazole derivatives acting as NLRP3 inflammasome inhibitors. As such, they are potentially useful for the treatment of atherosclerosis, ...

A new class of anti-inflammatory drug is opening a world of possibilities for treating everything from neurological diseases to cancers. Using technology he developed at Hudson Institute of Medical ...

Northwestern Medicine investigators recently discovered that the mitochondrial respiratory chain — a series of protein complexes essential for a cellular respiration and energy production — is ...

For the first time, researchers have captured the formation of a key driver of inflammatory responses inside intact human cells. Pioneering a new system for observing molecular assemblies, researchers ...

The activation of the NLRP3 inflammasome exacerbates neuronal dysfunction in several neurological diseases such as Alzheimer’s and Parkinson’s diseases, as well as multiple sclerosis. Targeting NLRP3 ...

CV, a 12-week, 160-patient Phase 2 proof-of-concept trial of its oral NLRP3 inhibitor BGE-102 in adults with obesity, elevated inflammation, and additional cardiovascular risk factors. An interesting ...

Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing differentiated therapies for neurodegenerative and neuroinflammatory diseases, today announced that Alexei ...

A new study suggests that statins may activate inflammatory "danger signals" inside muscle cells, leading to weakness and ...